Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 22: 1644-1647, 1976;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eisenberg, J.
Right arrow Articles by Goldfarb, S
Right arrow Search for Related Content
PubMed
Right arrow Articles by Eisenberg, J.
Right arrow Articles by Goldfarb, S

Clinical Chemistry, Vol 22, 1644-1647, Copyright © 1976 by American Association for Clinical Chemistry

Clinical usefulness of measuring prothrombin time as a routine admission test

JM Eisenberg and S Goldfarb

A questionnaire indicating the presence of a history or physical findings consistent with liver desease or bleeding disorders was completed by house officers on 301 admissions to a Veterans Administration medical service. Each patient had prothrombin time determined on admission. Only two of 107 patients for whom the prothrombin time was measured as a screening test had an abnormal results and one of these was normal when repeated. Of 73 patients with a history of alcoholism but no other pertient case history or physical examination results, only one had an abnormal prothrombin time. Of the remaining 121 patients, who had a pertinent history or physical examination, 41 had an abnormal admission prothrombin time. We conclude that measurement of prothrombin time adds little additional information to that obtained by history and physical examination in screening for liver disease and coagulation defects unless the patient has specific clinical evidence of liver disease, anticoagulation, or other conditions predisposing to bleeding disorders.


The following articles in journals at HighWire Press have cited this article:


Home page
ANN INTERN MEDHome page
M. H. Eckman, J. K. Erban, S. K. Singh, and G. S. Kao
Screening for the Risk for Bleeding or Thrombosis
Ann Intern Med, February 4, 2003; 138(3): W-15 - W-24.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by the American Association for Clinical Chemistry.